Search results
Jun 24, 2024 · Biocon is an innovation led fully integrated biopharmaceutical company that develop affordable biosimilars, generic formulations & complex APIs.
A global biopharmaceutical company changing patients’ lives by finding new & affordable ways to treat diabetes, cancer & autoimmune diseases.
Biocon Limited is an Indian biopharmaceutical company based in Bangalore. It was founded by Kiran Mazumdar-Shaw in 1978. The company manufactures generic active pharmaceutical ingredients (APIs) that are sold in approximately 120 countries, including the United States and Europe. It also manufactures novel biologics as well as biosimilar insulins and antibodies, which are sold in India as branded formulations. Biocon's biosimilar products are also sold in both bulk and formulation forms in ...
Get all the information on Biocon with historic price charts for NSE / BSE. Experts & Broker view also get the Biocon Ltd. buy/sell tips detailed news, announcements, Forecasts, Analysts ...
We are committed to providing everyone, everywhere, affordable access to a speciality portfolio of medicines. We are steadfastly investing in developing novel therapies for diabetes, oncology and immunology. We are strengthening our global reach and economies of scale.
Jun 24, 2024 · Driven by our collective vision of transforming healthcare and transforming patients’ lives, Biocon Biologics is making healthcare affordable and importantly accessible to millions of patients and their families across the world.
2 days ago · Biocon Share Price Today (03 Jul, 2024): Biocon Stock Price (₹ 361.00) Live NSE/BSE updates on The Economic Times. Check out why Biocon share price is up today. Get all details on Biocon Ltd.shares news and analysis, Forecasts, Dividend, balance sheet, profit & loss, Quarterly results, annual report information, and more
Biocon Limited is a globally recognized, innovation-led organization that is enabling access to high quality, advanced therapies for diseases that are chronic, where medical needs are largely unmet and treatment costs are high.
Biocon Biologics Ltd on Monday announced that it has received approval from the European Medicines Agency (EMA) to manufacture biosimilar Bevacizumab at its new multi-product monoclonal antibodies ...
Biocon Biologics is today one of the frontrunners in the global biosimilars industry, working to provide patients access to affordable biologics and enable health equity worldwide. Driven by a Purpose to Address Unmet Needs for Affordable Biologics.
